Bank of Montreal
MRSN

Bank of Montreal’s Mersana Therapeutics MRSN Stock Holding History

Bank of Montreal’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-2,140
Closed -$861K – 4465
2021
Q1 		$861K Buy
+2,140
New +$1.04M ﹤0.01% 2308
2020
Q3 		– Sell
-3,600
Closed -$2.03M – 4869
2020
Q2 		$2.03M Buy
+3,600
New +$1.23M ﹤0.01% 1631

Other funds holding MRSN

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Bank of Montreal's MRSN Position: Q2 2023 in Review

Bank of Montreal sold out of Mersana Therapeutics (MRSN) in Q2 2023, closing a stake of 820 shares — an estimated $85.6K sold.

Bank of Montreal first reported a position in MRSN in Q1 2018 and held it in 16 quarters. The position peaked at $4.67M in Q1 2022. 147 funds tracked by Wall St. Rank hold MRSN as of Q2 2023.

  • Bank of Montreal reported no remaining Mersana Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Bank of Montreal sold 820 Mersana Therapeutics shares in Q2 2023, an estimated $85.6K.
  • Bank of Montreal first reported a position in Mersana Therapeutics in Q1 2018 and held it in 16 quarters.
  • Bank of Montreal's Mersana Therapeutics position peaked at $4.67M in Q1 2022.
  • 147 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q2 2023.

Based on Bank of Montreal's 13F filing for Q2 2023, filed 2 Aug 2023.